Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL15656206 | 1.00 | HSD11B1 (0.39) | HSD11B1F2PRSS1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3899532 | 0.92 | HSD11B1 (0.37) | HSD11B1DPP4DPP8KMT2A | |
| Trifluoroacetic Acid SCHEMBL20956254 | 0.92 | HSD11B1 (0.37) | HSD11B1DPP4DPP8KMT2A | |
| Trifluoroacetic Acid SCHEMBL28525241 | 0.85 | HSD11B1 (0.38) | HSD11B1F2PRSS1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL15654913 | 0.85 | HSD11B1 (0.38) | HSD11B1F2PRSS1DPP4DPP8 | |
| SCHEMBL15655890 | 0.84 | JAK2 (0.33) | HSD11B1 | |
| SCHEMBL15655893 | 0.84 | JAK2 (0.33) | HSD11B1 | |
| Trifluoroacetic Acid SCHEMBL6475932 | 0.80 | GABRA5 (0.37) | HSD11B1 | |
| Trifluoroacetic Acid SCHEMBL3900775 | 0.79 | HSD11B1 (0.34) | HSD11B1DPP4DPP8CTSSCTSK | |
| Trifluoroacetic Acid SCHEMBL14737756 | 0.79 | HSD11B1 (0.34) | HSD11B1DPP4DPP8CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013007768-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| CN-102712640-A | Tricyclic heterocyclic compounds, compositions and methods of use thereof | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | HSD11B1 291/4885F2 143/4885PRSS1 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.